REFRACTORY AML
Clinical trials for REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY AML trials appear
Sign up with your email to follow new studies for REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell 'Bridge' offers new hope for tough leukemia
Disease control Recruiting nowThis study tests a new immune cell treatment called AdaptNK for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially selected natural killer cells from a donor, given after chemotherapy, to help control the…
Matched conditions: REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to tackle tough leukemia
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…
Matched conditions: REFRACTORY AML
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment made from a person's own immune cells, called CLL-1 CAR-NK cells, for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study aims to see if the treatment is safe and tolerable, …
Matched conditions: REFRACTORY AML
Phase: PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC